Celladon Corporation’s CLDN shares plummeted 80.7% following the company’s announcement that randomized, double-blind, placebo-controlled, multinational phase IIb study (CUPID2) on advanced heart ...
SAN DIEGO, April 26, 2015 -- Celladon Corporation (CLDN) today announced that its Phase 2b CUPID2 trial did not meet its primary and secondary endpoints. CUPID2 is a randomized, double-blind, ...
Celladon said yesterday its lead investigational product candidate, the cardiovascular gene therapy agent Mydicar® (AAV1/SERCA2a), did not meet its primary and secondary endpoints in the Phase IIb ...
SAN DIEGO, June 1, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), today announced that its Board of Directors has unanimously approved a strategic plan pursuant to which the Company will ...
The alternative text for this image may have been generated using AI. The largest study using gene transfer to treat advanced heart failure patients has yielded negative results, its sponsor Celladon ...
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. On its website, Celladon Corp. (NASDAQ: CLDN) writes ...
Pompey, France, and San Diego, CA, USA, March 24, 2015 - Novasep, a leading supplier of services and technologies for the life sciences and chemical industries, and Celladon Corporation (Nasdaq:CLDN), ...
Novasep, a leading supplier of services and technologies for the life sciences and chemical industries, and Celladon Corporation (Nasdaq:CLDN), a clinical-stage cardiovascular gene therapy company, ...
Novasep and Celladon Corporation have announced that they have signed a Development, Manufacturing and Supply Agreement pursuant to which, if supported by upcoming MYDICAR clinical data, Novasep would ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results